Efficacy of Personal Pharmacogenomic Testing as an Educational Tool in the Pharmacy Curriculum

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04889014

Enrollment

233

Registered

2021-05-17

Start date

2016-03-03

Completion date

2021-03-01

Last updated

2021-05-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy

Brief summary

The purpose of this study is to evaluate the use of personal genomic educational testing (PGET) on student knowledge and clinical skills surrounding pharmacogenomic testing to ensure it is of educational benefit to our student population. Students will be provided the opportunity to opt-in to test their own pharmacogenomic panel while participating in the standard curriculum. Students will have the option of using their own reports or dummy reports during classroom activities. Our hypothesis is that those students who have their own pharmacogenomics tested will show better overall performance.

Interventions

GENETICPersonal genomic educational testing (PGET)

PGET consisted of a panel of pharmacogenomic variants

GENETICNo personal genomic educational testing (NPGET)

Lack of pharmacogenomic testing

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

OTHER

Masking

SINGLE (Investigator)

Masking description

Instructors and all study personnel were blinded to participant PGET assignment, PGx results, and survey results.

Intervention model description

We investigated the effect of PGET on student knowledge, comfort, and attitudes related to pharmacogenomics (PGx) in a non-blinded, randomized controlled trial. Consenting participants were randomized to receive PGET or no PGET (NPGET) during four subsequent years of a PGx course.

Eligibility

Sex/Gender

ALL

Healthy volunteers

Yes

Inclusion criteria

* Willingness to provide informed consent for participation in the study * Enrolled in 3rd year Doctor of Pharmacy course

Exclusion criteria

* Unwilling or unable to provide consent for participation

Design outcomes

Primary

Measure	Time frame	Description
Change in Pharmacogenomics Knowledge Assessment	8-12 weeks	Improvement in performance on a knowledge assessment including eleven questions

Secondary

Measure	Time frame	Description
Change in Self Assessment Questionnaire	8-12 weeks	Improvement in Likert Scale Responses for 27 questions (scale of 1\[worst\] to 6\[best\])

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026